ERBB2 and neoplasm: This theory is supported by in vivo studies in mouse tumor models showing a significant response of H-cell-phenotype tumor cells to trastuzumab and T-Dxd treatments in HER2-low mouse tumor models (PDX and 231-HN, respectively) (Fig. 2F-K).